Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
WEGOVY- semaglutide tablet, DailyMed (2026) Lillys oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity, Lilly (2025) Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes, a randomized clinical trial, JAMA Network Open (2023) Pfizer provides update on oral GLP-1 receptor agonist danuglipron, Pfizer (2025) Oral semaglutide, Clinical Diabetes (2020) Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet (2023) A review of current guidelines for the treatment of obesity, American Journal of Managed Care (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Insurance, diagnosis and where you fill the prescription all play a role and most people don't know they have options
Why Exercise Becomes Even More Important When transitioning off GLP-1 meds, exercise becomes your anchor
Platform-by-platform comparison Several patterns emerge from this comparison
Youve been temporarily blocked from using it
